Several small-molecule JAK inhibitors and STAT3 antisense oligonucleotides are currently in clinical trials for hematologic malignancies, including drug-resistant or relapsed BCL cells.22, 52 Whether their efficacy partly relies on immune-mediated effects is not yet clear. Here, STAT3 is linked to hematologic disorder.